US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
Sanofi would not manufacture or market any product which infringes the amended claims of Panacea patent, IN272351
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
The sANDA was submitted as “Prior Approval Supplement” for addition of an alternate drug product manufacturing, labeling, packaging, and testing facility
Increases efficiency by 70% compared to stainless steel or glass manufacturing methods
The company is making its mark through strategic initiatives, promising to become a significant presence in the evolving pharmaceutical sector
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Innovative technologies and comprehensive services to strengthen Syntegon’s strategic growth
Subscribe To Our Newsletter & Stay Updated
